BeiGene Oncology (ONC) Net Margin

Brandmark of BeiGene Ltd. (ONC)

The sales margin of BeiGene Ltd demonstrates the efficiency of Asian development followed by the introduction of high-cost oncology drugs to Western markets, with the 13.90 metric serving as the target level. High scalability is driven by global distribution following the completion of costly trials. The company's organic growth relies on strategic partnerships with the world's largest pharma behemoths.

beigene.com (ONC) - Net Margin from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for BeiGene Ltd (ONC)

- share price and expert price forecast:
- market capitalization details:
Fundamental company valuation:BeiGene Corp - ONC
Manufactured product of BeiGene Oncology

The aggressive commercialization of BeiGene Ltd. (ONC) products under the leadership of John Euler in the US and China is clearly reflected in the net profit margin chart. This indicator is calculated as the ratio of net income to total revenue, measuring the actual earnings share of every dollar of sales, which allows investors to assess the business's operational efficiency and the risks of capital drawdown.

Key competitors

Halozyme Corp (HALO) - Net Margin|Net Margin Revolution Medicines Inc (RVMD)|Net Margin Ascentage Pharma Group|Net Return on Sales CGON (CG Oncology Corp)|Net Margin UroGen Pharma (URGN)|Net Sales Margin Bicara Therapeutics (BCAX)|Net Sales Margin PSNL (personalis.com)|Net Profit Rate ERAS|DCTH: Return on Sales by Net Profit|YmAbs - Company Net Profitability|aurabiosciences.com (AURA) - Net Margin|Candel Therapeutics Inc. - Net Profit Rate|Net Margin Accuray Inc.|Net Margin SELLAS Life Sciences Group SLS|Net Sales Margin ACTU|CTOR - Net Margin|Net Sales Margin HURA (TuHURA Biosciences, Inc.)|Net Profit Rate TARA|FATE: Return on Sales by Net Profit|WHWK (aadibio.com) - Net Return on Sales|TCRX (TScan Therapeutics, Inc.) - Return on Sales by Net Profit|Net Margin Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)